Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 59c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $0.30, $0.59 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $42.1 million versus the consensus estimate of $28.61 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst